
The FDA approved adrabetadex for infantile-onset NPC based on a 55% lower risk of death vs external controls, with a boxed warning for hearing loss.
In January, implementation of the federal government's plan to vaccinate 500,000 civilian health-care workers and emergency response teams against smallpox was begun.






